2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendationsLes lignes directrices canadiennes 2009 de la Société canadienne de cardiologie pour le diagnostic et le traitement de la dyslipidémie ainsi que pour la prévention des maladies cardiovasculaires chez l’adulte – Des recommandations pour 2009
References (79)
- et al.
Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement – recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
Can J Cardiol
(2006) - et al.
The metabolic syndrome – a new worldwide definition
Lancet
(2005) - et al.
The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population-based study
Clin Gastroenterol Hepatol
(2008) - et al.
The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
Am J Cardiol
(2008) - et al.
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)
Am J Cardiol
(2008) - et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
Lancet
(2004) - et al.
Metabolic syndrome and risk of cardiovascular disease: A meta-analysis
Am J Med
(2006) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
Lancet
(2003) - et al.
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic Groups (SHARE)
Lancet
(2000) - et al.
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 trials)
Am J Cardiol
(2007)
Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl
Am J Cardiol
(2009)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
Lancet
(2009)
American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine
J Am Soc Echocardiogr
(2008)
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g)
Am J Cardiol
(2008)
Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women
JAMA
(2005)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
N Engl J Med
(2008)
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults – a prospective study of parents and offspring
JAMA
(2004)
Family history as a risk factor for primary cardiac arrest
Circulation
(1998)
Abdominal obesity and metabolic syndrome
Nature
(2006)
Prevalence of class I, II and III obesity in Canada
CMAJ
(2006)
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus
Arthritis Rheum
(1999)
Cardiovascular morbidity in psoriatic arthritis
Ann Rheum Dis
(2009)
Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus
Arthritis Rheum
(2003)
Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: Results from a systematic review and meta-analysis
Am J Gastroenterol
(2007)
Class of antiretroviral drugs and the risk of myocardial infarction
N Engl J Med
(2007)
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
(2005)
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
N Engl J Med
(2007)
Homocysteine lowering with folic acid and B vitamins in vascular disease
N Engl J Med
(2006)
AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute
Circulation
(2006)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
N Engl J Med
(2004)
Kidney disease as a risk factor for development of cardiovascular disease – a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Circulation
(2003)
Metabolic syndrome associated with HIV and highly active antiretroviral therapy
Curr Diab Rep
(2009)
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events
Circulation
(2003)
Lipoprotein(a) and coronary heart disease – meta-analysis of prospective studies
Circulation
(2000)
Consensus panel recommendation for incorporating lipoprotein associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines
Am J Cardiol
(2008)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging biomarkers for primary prevention of cardiovascular disease
Clin Chem
(2009)
Cited by (0)
Copyright © 2009 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.